Table 1.
Selected candidate genes for mutation frequency analysis among the included HCC patients
| Gene | Descriptiion | Mutation frequency | #Snv/Kbp | No. COSMIC matched | No. recurrence | P value | False discovery rate |
|---|---|---|---|---|---|---|---|
| TP53* | Tumor protein p53 | 64% (21) | 7.31 | 15 | 3 | 0 | 0 |
| ARID1A | AT rich interactive domain 1A (Tumor-suppressor) | 24% (8) | 0.68 | 3 | 1 | 0 | 0 |
| FLCN | Folliculin | 9.1% (3) | 8.4 | 1 | 0 | 0 | 0.01 |
| SETD2 | SET domain containing 2 (Tumor-suppressor) | 9.1% (3) | 0.52 | 0 | 0 | 0 | 0.055 |
| PTEN | Phosphatase and tensin homolog (Tumor-suppressor) | 12.1% (4) | 1.43 | 0 | 0 | 0 | 0.2 |
| BUB1B | Budding uninhibited by benzimidazoles 1 homolog beta (Tumor-suppressor) |
9.1% (3) | 4.05 | 0 | 0 | 0 | 0.2 |
| CTNNB1* | Catenin (cadherin-associated protein), beta 1, 88kDa | 6.1% (2) | 4.36 | 2 | 0 | 0.019 | 1 |
| JAK1* | Janus kinase 1 | 9.1% (3) | 7.28 | 1 | 0 | 0.193 | 1 |
| AXIN1* | Axin 1 | 21.2% (7) | 1.59 | 2 | 0 | 0.426 | 1 |
| EPS15* | Epidermal growth factor receptor pathway substrate 15 | 6.1% (2) | 6.01 | 1 | 0 | 0.61 | 1 |
| CACNA2D4* | Calcium channel, voltage-dependent, alpha 2/delta subunit 4 | 9.1% (3) | 9.4 | 0 | 0 | 0.003 | 1 |
Note: TP53, CTNNB1, AXIN1, JAK1, EPS15, and CACNA2D4 were recognized as significantly mutated genes in HCC. *ARID1A, FLCN, SETD2, PTEN, and BUB1B were well known to be frequently mutated in other types of cancer.
Abbreviations: HCC, hepatocellularcarcinoma; No., number.